Drug intelligence / Profile preview

nanoenzalutamide

Development stage: Preclinical
Lead developer: Nanoform
Modality: Nanoparticles → Drug Delivery Systems, Small Molecules
Administration: Oral

Overview

**Nanoenzalutamide** is a nanotechnology-enhanced formulation of enzalutamide, used for treating prostate cancer. It works by inhibiting androgen receptors, which are involved in the growth and spread of prostate cancer cells. This formulation is designed to improve patient compliance by reducing pill burden and enhancing bioavailability. It is developed using Nanoform's proprietary CESS technology.

Other names: nanocrystalline-enabled enzalutamide

Targets

AR (Adrenergic receptors)

Beyond the preview

Go deeper on nanoenzalutamide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on nanoenzalutamide.

Explore the full profile